| Private Placement / Financing Transactions
Flare Therapeutics: The company raised $123 million of Series B venture funding in a deal led by Pfizer Ventures and GordonMD Global Investments on March 22, 2023, putting the company’s pre-money valuation at $150 million. Eli Lilly, Memorial Sloan Kettering Cancer Center, Novartis, Pavilion Capital Partners, Invus Financial Advisors, ShangBay Capital, Agent Capital, Third Rock Ventures, Boxer Capital, Nextech Invest, Casdin Capital and Eventide Asset Management also participated in the round. The company is an operator of a health-tech platform intended to offer small-molecule precision medicine for cancer patients.
Artera: The company raised $90 million of venture funding from Johnson & Johnson Innovation – JJDC, Coatue Management and Koch Disruptive Technologies on March 21, 2023. Walden Catalyst and 14 other investors also participated in the round. The company is an operator of a precision medicine company developing artificial intelligence (AI) tests intended for cancer patients.
Cognito Therapeutics: The company raised $73 million of Series B venture funding in a deal led by FoundersX Ventures on March 22, 2023. Starbloom Capital, Wilson Sonsini Goodrich & Rosati, Alzheimers Drug Discovery Foundation, and IAG Capital Partners also participated in the round. The company is a developer of disease-modifying digital therapeutics intended to cure neurodegenerative disorders.
Apprentice: The company raised an additional $65 million through a combination of debt and Series C1 funding in a deal led by ICONIQ Capital on March 20, 2023, putting the company’s pre-money valuation at $527.25 million. Insight Partners and Alkeon Capital Management also participated in the round. The company is a developer of an intelligent manufacturing execution system designed to help life science businesses to meet the demand for getting life-saving drugs to market.
Empirico: The company raised $45.2 million of venture funding from undisclosed investors on March 20, 2023. The company is a developer of an insights platform designed to turn biological insights from human genetics into new medicines.
GT Medical Technologies: The company raised $45 million of Series C venture funding in a deal led by Gilde Healthcare on March 23, 2023. MVM Partners, Medical Technology Venture Partners, and BlueStone Venture Partners also participated in the round. The company is a developer of a medical therapeutic technology designed to overcome the limitations of current treatments for recurrent brain tumors.
Cellanome: The company raised $40.7 million of Series A2 venture funding from 8VC, HBM Genomics, and DCVC Bio on March 21, 2023. The company is a developer of a unique multi-omics platform designed to measure biology at an unprecedented resolution and scale.
Proxim Diagnostics: The company raised $18 million of Series D venture funding from BioMérieux and other undisclosed investors on March 21, 2023, putting the company’s pre-money valuation at $75 million. The company is a developer of an immunodiagnostic device intended to market a new generation of diagnostic tests on a handheld platform.
Unlearn: The company raised $15 million of Series B1 venture funding from Radical Ventures, Wittington Ventures and other undisclosed investors on March 21, 2023, putting the company’s pre-money valuation at $250 million. The company is a developer of a machine-learning platform designed to create digital twins used to populate intelligent control arms in clinical studies.
Mbiomics: The company raised EUR 13 million of Series A venture funding in a deal led by MIG Capital on March 23, 2023. High-Tech Gründerfonds and Bayern Kapital along with other undisclosed investors also participated in the round. The company is an operator of a microbiome research firm focused on microbiome research, diagnostics, and therapeutics.
Pragma Biosciences: The company raised $10 million of venture funding in a deal led by The Venture Collective on March 23, 2023. Merck Global Health Innovation Fund, CJ Investment, Viking Global Investors, and other undisclosed investors also participated in the round. The company is an operator of a biotechnology agency focused on cancer therapy through the microbiome.
Mingle Health: The company raised $8.7 million of venture funding in a combination of equity and convertible notes from undisclosed investors on March 20, 2023. The company is an operator of a healthcare informatics platform.
DermBiont: The company raised $7.2 million of venture funding in the form of convertible debt from undisclosed investors on March 21, 2023. The company is a developer of microbial therapeutics designed to impact the root causes of skin diseases.
Minute Molecular: The company raised $6.1 million of venture funding from undisclosed investors on March 22, 2023. The company is a developer of a molecular diagnostics device designed to provide rapid immunoassays.
Phase Genomics: The company raised $4.8 million of venture funding in the form of convertible promissory notes from undisclosed investors on March 21, 2023. The company is a developer of a biotechnology platform for new discoveries in fields such as agriculture, human health, and industrial biology.
Serotiny: The company raised $4 million of venture funding in the form of convertible debt from undisclosed investors on March 20, 2023. The company is an operator of a biotechnology platform intended to develop genes encoding for therapeutic multi-domain proteins.
|
